Final hours! Save up to 55% OFF InvestingProCLAIM SALE

Amgen 2020 outlook falls short of Street estimates, shares down 3%

Published 01/30/2020, 05:30 PM
Updated 01/30/2020, 05:34 PM
Amgen 2020 outlook falls short of Street estimates, shares down 3%
AMGN
-
6160
-

By Deena Beasley

(Reuters) - Amgen Inc (O:AMGN) on Thursday forecast 2020 earnings well short of current Wall Street estimates, sending shares of the largest U.S. biotechnology company down 3%.

For the full year, the company forecast earnings of $14.85 to $15.60 per share on revenue as high as $25.6 billion. Analysts had estimated 2020 adjusted earnings of $16.14 on revenue of $25.5 billion, according to Refinitiv IBES data.

A company official attributed the difference to lower interest income and Amgen's recently acquired 20.5% stake in China's BeiGene Ltd (HK:6160), which is not yet profitable.

For the fourth quarter of last year, Amgen said its sales fell 2% from a year earlier due to competition from lower-cost generic drugs and biosimilars, but share buybacks enabled the company to post a profit that topped Wall Street estimates.

Sales for the quarter totaled $5.88 billion. Total revenue fell 1% to $6.2 billion, which was ahead of the average analyst estimate of $6.06 billion.

Quarterly adjusted earnings per share rose 6% to $3.64, beating the average Wall Street estimate of $3.48.

Net earnings fell 5% to $2.85 per share due to higher operating costs partially offset by a lower share count.

Sales of older drugs such as white blood cell booster Neulasta and kidney drug Sensipar fell sharply due to competition from cheaper versions. Neulasta was down 43% at $665 million and Sensipar sales were off by 76% at $107 million.

Sales of newer drugs like cholesterol fighter Repatha and migraine drug Aimovig rose. Repatha was up by 26% to $200 million, while Aimovig rose 3% to $98 million in the quarter.

Amgen said it bought back around 6% of its outstanding shares last year.

Shares of the company were down $7.15, or 3.2%, at $219 in after hours trading.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.